-
Toxoplasmosis in immunocompetent patients (FDA approved)
- Has been used off label for Toxoplasmosis in HIV and Congenital Toxoplasmosis
- Previously used to treat Malaria
- Replaced by other agents due to Malaria resistance to Pyrimethamine
- Has also been used as an antimalarial in combination with Sulfadoxine (Fansidar)
- Synthetic derivative of ethyl Pyrimidine with Antiparasitic and antimalarial activity
- Competitive inhibitor of dihydrofolate reductase (DHFR).
- DHFR is a key enzyme in Tetrahydrofolate synthesis, and in turn DNA and Protein synthesis
- Tablet: 25 mg
- Only available directly from manufacturer
- Used in combination with leucovorin and Sulfadiazine
- Combined with leucovorin to prevent hematologic adverse effects
- Combined with Sulfadiazine to broaden coverage
- Dosing is for immunocompetent patients
- See other resources for HIV related ToxoplasmosisEncephalitis
- See other resources for Congenital Toxoplasmosis
- Adult
- Start 50 to 75 mg orally daily for 1 to 3 weeks (use lower dose in Seizure Disorder)
- Next decrease dose 50% daily for an additional 5 weeks
- Child
- Start 1 mg/kg/day orally twice daily for 2 to 4 days
- Next decrease dose 50% for an additional 4 weeks
- Pregnancy Category C
- Considered safe in Lactation
loading